SCHEMBL6399251

SCHEMBL6399251

O=P(O)(O)Sc1ccc(O)cc1CCCCc1ccc(O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.42
ALOX15 P16050 1/20 0.42
ESR1 P03372 4/20 0.40
ACHE P22303 3/20 0.40
ADRA2A P08913 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
TACR2 P21452 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SHBG P04278 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
HSPD1 P10809 1/20 0.40
ADRB3 P13945 1/20 0.40
HTR2C P28335 1/20 0.40
HSPE1 P61604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6394285 0.97 SLC28A3 (0.41) IGF1RALOX15ESR1ACHEADRA2A
SCHEMBL6401556 0.91 ESR1 (0.44) ALOX15ESR1ADRA2ASLC6A2KDM4E
SCHEMBL6396039 0.89 MGLL (0.46) CHRM2CHRM1CHRM3MGLLAKR1B10
SCHEMBL6395960 0.88 ALOX15 (0.42) IGF1RALOX15ESR1ACHEADRA2A
SCHEMBL6401883 0.86 CALM1 (0.45) CHRM2CHRM1CHRM3MGLLAKR1B10
SCHEMBL6395871 0.85 ESR1 (0.44) IGF1RALOX15ESR1ACHEADRA2A
SCHEMBL6395985 0.79 DRD2 (0.44) EGFRLCKCHRM2CHRM1CHRM3
SCHEMBL6395752 0.79 MGLL (0.45) CHRM2CHRM1CHRM3MGLLAKR1B10
SCHEMBL6396938 0.79 ESR1 (0.44) ALOX15ESR1ADRA2ASLC6A2KDM4E
SCHEMBL6402014 0.78 IGF1R (0.36) IGF1RALOX15ESR1ACHEADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 IGF1R 1022/4885ALOX15 2521/4885ESR1 2885/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 IGF1R 1022/4885ALOX15 2521/4885ESR1 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.